The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

Six drugmakers who have violated the 340B statute should immediately begin offering drugs at discounted prices to hospitals participating in the federal drug-pricing program, according to a letter ...

Hospitals that serve a high volume of low-income and uninsured patients rely on Disproportionate Share Hospital (DSH) funding to maintain financial stability. A hospital’s DSH percentage is critical ...

Jeff Davis, a partner in the Washington, D.C., law office of Bass, Berry & Sims, advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the ...

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

Mere days before the Health Resources and Services Administration’s (HRSA) 340B Rebate Model Pilot Program’s (“Pilot”) scheduled January 1, 2026 effective date, a federal district court granted a ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. In Maine, the 340B drug program was meant to be a structure of care — a ...